Akron gave us rubber, New York gave us Wall Street, and now Optain Health is giving us something far more valuable: the ability to see disease before it takes hold. The company just closed a $26 million Series A led by Insight Partners, backed by seven major U.S. health systems that collectively serve 28 million patients across 25 states. This isn’t small-time capital chasing a shiny AI toy. This is scale, strategy, and science converging around one truth: your eyes don’t just show you the world, they reveal the state of your body.
Optain Health was born in 2023, but its roots run deeper. The story began with Eyetelligence, an Australian venture founded in 2019 by Professor Mingguang He. When Ascertain, a collaboration between Aegis Ventures and Northwell Holdings, dropped $12 million in 2023 to bring the technology stateside, the game shifted. Eyetelligence became Optain Health, headquartered in New York, with a mission to apply artificial intelligence, robotic retinal imaging, and teleophthalmology to screen for over 140 conditions. Call it oculomics, the science of using the eye as a diagnostic portal for the whole body.
This Series A isn’t just validation, it’s acceleration. Memorial Hermann, Northwell Health, Novant Health, The Ohio State University Wexner Medical Center, and UPMC aren’t just investors, they’re strategic partners. Add Informed Ventures, Lumio Capital, Meridian Ventures, and UniQuest Extension Fund, and you’ve got a syndicate betting on retinal AI to become as standard in primary care as the blood pressure cuff.
Leadership is stacked with precision operators. CEO Jeff Dunkel brings strategy muscle from Titan Spine and Johnson & Johnson. President Zachary Tan, MD, is a physician-scientist with Aegis Ventures and a Schwarzman Scholar. Chief Medical Officer and co-founder Professor Mingguang He is one of the world’s leading authorities on retinal AI. Chief Research Officer Associate Professor Zongyuan Ge pushes the frontier of medical machine learning at Monash University. And Dr. John Noseworthy, Emeritus CEO of Mayo Clinic, is watching closely as board observer. If you want credibility, that isn’t a bench, it’s a power play.
Optain’s platform is built on Resolve, a portable retinal camera, and Assure, the diagnostic software. Together, they capture images without dilation, run them through AI trained on 30 million retinal scans, and deliver real-time analysis on conditions ranging from diabetic retinopathy to cardiovascular risk. In Australia, they’ve already partnered with Bupa Optical and George & Matilda. Now U.S. health systems are the next frontier.
This round brings total funding to $38 million, but the real metric isn’t dollars, it’s access. When technology this sharp lands in primary care, optometry, and specialty clinics, it closes gaps, lowers costs, and spots what the naked eye misses. The lesson for the industry is clear: the next wave of diagnostics won’t come from blood, MRI, or genetic sequencing alone. Sometimes the fastest route to systemic insight is staring us in the face.
